Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Byetta Prescribers for Diabetes

Articles with lock require a subscription to GLG News | Request a free trial
September 3, 2007
Diabetes Medications Are For Sugars; Statins and Hypertensives Are For Hearts
Analysis of: FDA Adviser Questions Surrogate Endpoints for Diabetes Drug Approvals | www.medpagetoday.com
Author: GLG Expert Contributor
To demand diabetes medications have positive outcomes would be akin to asking for proof that antibiotics save lives or statins lower blood sugars. If this be law, we would have very few drugs and lots of sick patients.
August 21, 2007
Avandia And The Story Of Humpty Dumpty
Analysis of: GlaxoSmithKline updates prescribing information for Avandia in the US | www.pipelinereview.com
Author: GLG Expert Contributor
The Black Box CHF Warning for Avandia and Actos, is not new information. It merely defects the real issue-- the risk of overall cardiac events.
August 20, 2007
SYMLIN-All this poken' could lead to one smoken'
Analysis of: SYMLIN(R) Used in Conjunction with Basal Insulin in Patients with Type 2 Diabetes | www.pipelinereview.com
Author: GLG Expert Contributor
Too much hastle for too little benefit
August 16, 2007
Keep Drinking Soft Drinks, and Keep the Diabetes Industry Alive!
Analysis of: Framingham Observational Study Notes Greater Incidence Of Metabolic Syndrome Among Adults Consuming Soft Drinks | www.medicalnewstoday.com
Author: GLG Expert Contributor
People, in general, who may have other concerns than their health, consume soft drinks, both regular and diet. High fructose corn syrup in our society is like lead to the Romans. Why is taking our government so long to figure this out?
August 13, 2007
not always
Analysis of: Older and cheaper pills just fine for diabetes | www.reuters.com
Author: GLG Expert Contributor
1-diabetics are an extremely diverse group of people 2-co-morbidities, stage of disease, and the pancreatic reserve all govern the ideal regimen for a certain patient 3-the more options we have, the better equipped we are to help more patients 4-glycemic control is not the only decisive factor when...
July 30, 2007
Bristol-Myers Diabetes Drug, A Novel Mechanism, A Long Road To Haul
Analysis of: Bristol-Myers Drug, First in New Family, Controls Blood Sugar | www.bloomberg.com
Author: GLG Expert Contributor
Dapagliflozin has a long way to go to prove its efficacy and safety as a potential diabetes medication. However, innovative medications are welcome as they will be pieces of the diabetic solution puzzle.
July 25, 2007
Efficacy of fexofenadine
Analysis of: Ranbaxy Receives Tentative FDA Approval For Fexofenadine Hydrochloride Tablets | www.medicalnewstoday.com
Author: GLG Expert Contributor
Fexofenadine-Allegra is usually perceived as slightly less effective than Claritin for seasonal allergic rhinitis. Both of these drug are non-sedating. Zyrtec, however, with slight sedation potential is the most powerful of the group.
July 25, 2007
the avandia saga
Analysis of: Small Physician Practices Struggle With Profitability | www.prnewswire.com
Author: GLG Expert Contributor
Many doctors are taking patients off of this drug after the NEJM article and ADA symposium. This brings out many concerning facts about this drug and its history. First, that this data was known years ago and not made public by GSK.  Second, that there is little reason now to treat patients with...
July 25, 2007
Galvus is way behind the eight ball in diabetes care.
Analysis of: Galvus(R), a new oral treatment for type 2 diabetes, receives positive opinion recommending European Union approval | www.pipelinereview.com
Author: GLG Expert Contributor
Galvus does not seem to have a competitive edge over Januvia, its main competition. Galvus needs to demonstrate a yet unknown significant advantage to gain significant market share.
July 19, 2007
Older diabetic medications are far from being adequate
Analysis of: Older and cheaper pills just fine for diabetes | www.reuters.com
Author: GLG Expert Contributor
Long-term comparisons of glycemic control are lacking between newer and older diabetes medications. However this is a one-dimensional comparison. Newer medications have significant other advantages over the older medications, but both are needed to safely reach glycemic goals.

Previous Page : 1 2 3 4 5 6 7 8 9 10 Next51 to 60 of 93

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T13:45:22.747